📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma? (2019)

First Author: Badi Y

Attributed to: Developing methods for multi-omic data integration and utilisation in pharmaco-genetic and -genomic analysis of drug responders and non-responders funded by BBSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1183/13993003.congress-2019.oa1606

Publication URI: http://dx.doi.org/10.1183/13993003.congress-2019.oa1606

Type: Conference/Paper/Proceeding/Abstract